Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Receives Grant from Food and Drug Administration for Clinical Study of Genetic Retinal Disease
Ongoing Phase II Trial tests ability to deliver sustainable treatment in patients with Leber congenital amaurosis (LCA) using proprietary AAV technology.
View HTML
Toggle Summary Bellingham brothers get experimental gene therapy in attempt to save their sight
Bellingham brothers get experimental gene therapy in attempt to save their sight When 11-year-old Casey Catalan goes on a walk in his Bellingham neighborhood, he hustles to be home before twilight. Once the sun fades, so does Casey's vision, because of a congenital eye disease.
View HTML
Toggle Summary AGTC and Icagen Announce Technology Transfer Agreement
AGTC and Icagen Announce Technology Transfer Agreement June 24, 2010 – AGTC, a privately held company, and Icagen, Inc. (NASDAQ: ICGN) today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies.  Icagen is transferring its rights to
View HTML
Toggle Summary AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases
AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases Combined Funds and Resources to be used to further demonstrate the AGTC’s AAV system’s ability to deliver sustainable treatments for human retinal diseases.
View HTML
Toggle Summary AGTC Raises $11,800,000 VC Financing
Proceeds to be used for advancement of treatment for inherited emphysema and development of treatments for genetic ocular diseases.
View HTML
Toggle Summary AGTC Expands its Clinical and Regulatory Expertise with Appointment of Jeffrey Chulay M.D. as Vice President of Chief Medical Officer
AGTC Expands its Clinical and Regulatory Expertise with Appointment of Jeffrey Chulay M.D. as Vice President of Chief Medical Officer July 9 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that Dr.
View HTML
Toggle Summary AGTC Receives $2 Million Milestone from Genzyme After Successful Transfer of Novel Production Technology
AGTC Receives $2 Million Milestone from Genzyme After Successful Transfer of Novel Production Technology June 21, 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that it has received a $2 million milestone payment
View HTML
Toggle Summary MIT, Caltech- and the Gators?
MIT, Caltech- and the Gators? How the University of Florida moved to the major league of technology startups. Read the Business Week article
View HTML
Toggle Summary AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease
AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease May 16, 2006 – The Juvenile Diabetes Research Foundation has joined in a partnership with AGTC (Applied Genetic Technologies Corp.) and Genzyme Corporation to develop a gene therapy treatment to potentially prevent
View HTML
Toggle Summary AGTC Announces Initiation of New Phase 1 Clinical Trial
AGTC Announces Initiation of New Phase 1 Clinical Trial February 23, 2006 - Applied Genetic Technologies Corporation (AGTC), a private clinical-stage biotechnology company, announced today the initiation of a Phase 1 clinical study to test the safety of AGTC-0106, its investigational gene therapy
View HTML
Visionary science for life changing cures.